Dimerix had their EU deal done before interim ph3 read out...

Dimerix had their EU deal done before interim ph3 read out showed efficacy... and their ph2 results tanked, so ph3 is simply a big bet that results will improve due to longer time of dosing. They still dont know how good their drug is as the trial is blinded, hence its low mc of just a couple hundred.

if dimerix can get a solid partner before real data why cant we, with a solid data history across multiple indications.

A low $10m upfront isnt much risk for big money pharm (as per dimerix). Risk either way; lose 10-20m now in the unlikely event results are somehow entirely diff from all previous studies, and are a disaster. Or wait and risk paying an extra 20m or much much more due to hungrier competition if results are as expected, or better.

i dont know why we're trading around 8c, but is it so much volume one could use it to fund a cr? Dont think so.